Member-only story
Metformin’s Potential in Reducing Long COVID — A Game Changer?
Three to six months after recovering from COVID-19, about 80–89 % of patients present with some symptoms, including fatigue and dyspnea, indicating long COVID that significantly influences the health-related quality of life of individuals who have had COVID-19.While there is no panacea for long COVID, an innovative clinical trial has found that metformin, which is used to treat diabetes, and other non-diabetic disease, may have substantial preventative effects to reduce the long-term damaging complications of COVID-19.e. Although no specific cure for long COVID exists, a groundbreaking clinical trial suggests that metformin, a widely used diabetes medication, may offer significant protective benefits — even for non-diabetic individuals.
A Promising Result for Non-Diabetics
A study conducted by the University of Minnesota showed that patients who took metformin ending four days from the first sign, of coronavirus symptoms reduced the risks of getting long COVID by 40% to 63%. This placebo-controlled clinical trial retrospective including more than 1200 adults evaluated the impact of metformin in combination with other medications such as ivermectin, fluvoxamine that did not reveal the same anti-long COVID activity. Overall, these data indicate that metformin might alleviate the phenomena of…
